Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December

Core Insights - Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing curative targeted cell therapies for autoimmune diseases [2] - The company will participate in several investor conferences in November and December 2025, providing opportunities for investor engagement [1][3] Company Overview - Cabaletta Bio utilizes the CABA™ platform, which includes two strategies aimed at developing engineered T cell therapies for autoimmune diseases [2] - The lead strategy, CARTA, focuses on the investigational therapy rese-cel, a fully human CD19-CAR T cell therapy [2] - Rese-cel is currently being evaluated in the RESET™ clinical development program across multiple therapeutic areas, including rheumatology, neurology, and dermatology [2] Upcoming Events - The company will host a webcasted fireside chat at the Guggenheim's 2nd Annual Healthcare Innovation Conference on November 11, 2025 [3] - Additional events include a fireside chat at the TD Cowen Immunology & Inflammation Summit on November 13, 2025, and the Jefferies Global Healthcare Conference on November 17, 2025 [3] - The company will also participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, and Citi's 2025 Global Healthcare Conference on December 3, 2025 [3]